Abstract 675P
Background
JSKN003 is a novel HER2-directed antibody-drug conjugate (ADC) conjugated to a topoisomerase I inhibitor via a dibenzocyclooctyne tetrapeptide linker on the glycans of a humanized bispecific antibody. JSKN003-101 and JSKN003-102 is dose escalation and expansion studies in Australian and Chinese patients (pts) with metastatic solid tumors.
Methods
This is pooled analysis from pts enrolled in JSKN003-101 and JSKN003-102 with histologically documented HER2-positive (IHC 3+) solid tumors who failed prior systemic therapies, received JSKN003 monotherapy intravenously Q3W. The objectives were safety and efficacy of JSKN-003.
Results
As of 15th Mar 2024, 24 pts (7 CRC, 5 GC, 3 ESCA, 2 OC, 2 BTC, and 5 others) were enrolled and JSKN003 dosed across 6 dose levels, including 2.1 mg/kg, 4.2 mg/kg, 5.2 mg/kg, 6.3 mg/kg, 7.3 mg/kg and 8.4 mg/kg. 10 pts (41.7%) received ≥ 3 prior lines of therapy,6 pts(25%) received anti-HER2 ADC. The median duration of treatment was 13.9 (range,9.4,19.8) weeks, and 20 pts (83.3%) remained on treatment. Treatment-related adverse events (TRAEs) occurred in 23 pts (95.8%), and the mostly common grade 1 and 2 TRAEs were diarrhea (62.5%) and nausea (58.3%), infusion related reaction (29.2%), fatigue (25.0%).5 pts (20.8%) experienced grade ≥3 TRAEs, were neutropenia (8.3%), vomiting (4.2%), fatigue (4.2%) and abdominal discomfort (4.2%). 2 pts had interstitial lung disease, grade 2 (occurred in 6.3 mg/kg), both recovered thereafter. No TRAE led to death or discontinuation. 22 pts with tumor assessment, the ORR and DCR were 72.7% (95%CI: 49.8, 89.3) and 95.5% (95%CI: 77.2, 99.9). 5 pts who received prior anti-HER2 ADC, the ORR was 80% and median DOR was more than 30 weeks.
Conclusions
JSKN003 was well tolerated with encouraging preliminary antitumor activity in heavily pretreated pts with advanced HER2-positive (IHC ≥ 3+) solid tumors, which support further clinical development.
Clinical trial identification
NCT05494918; NCT05744427.
Editorial acknowledgement
Legal entity responsible for the study
Alphamab Oncology.
Funding
Alphamab Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
683TiP - A phase I study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: The NiraPim (EPOC2102) study
Presenter: Hiromichi Nakajima
Session: Poster session 01
684TiP - A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors
Presenter: Bhumsuk Keam
Session: Poster session 01
685TiP - A phase I, multicenter trial (“KinLET”) of [177Lu]Lu-edotreotide for treatment of somatostatin receptor positive solid tumors or lymphoma, in patients two to less than 18 years of age
Presenter: Maria Cristina Mata Fernandez
Session: Poster session 01
687TiP - A phase I, first in human study of TORL-4-500 in patients with advanced cancer
Presenter: Jonathan Goldman
Session: Poster session 01
688TiP - Phase I dose escalation trial to evaluate safety and preliminary efficacy of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors
Presenter: Xihui Hu
Session: Poster session 01
689TiP - A phase I/IIa trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors
Presenter: Vaia Florou
Session: Poster session 01
690TiP - HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
Presenter: Thomas Powles
Session: Poster session 01
691TiP - PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
Presenter: Alison Schram
Session: Poster session 01
722P - Long-term patient-reported outcomes (PROs) with atezolizumab (atezo) + bevacizumab (bev) and chemotherapy (CT) for metastatic, persistent or recurrent cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial
Presenter: Laurence Gladieff
Session: Poster session 01